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Lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) are highly prevalent in older men. The storage 
subcategory of LUTS is synonymous with overactive bladder (OAB) syndrome, which is an empirical diagnosis. Traditionally, alpha-
blockers are widely prescribed to manage the LUTS of BPH, although storage symptoms may persist in many men despite treatment. 
Therefore, because therapies that target the prostate often fail to alleviate storage symptoms, they may not be the appropriate therapy 
for OAB. In past years, most physicians appeared to give more weight in elderly men to voiding symptoms than to storage symptoms 
and to be more concerned with initial treatment with anticholinergics for males with storage symptoms. Considering the recent 
increase in data on the efficacy and safety of combination treatment with alpha receptor antagonists and antimuscarinic agents, 
the standard pharmacologic treatment of patients with LUTS combined with OAB should be an alpha receptor antagonist and an 
antimuscarinic agent. Beta-3 adrenoreceptor agonists may also potentially be useful for the treatment of male LUTS combined with 
OAB. 
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INTRODUCTION 
Lower urinary tract symptoms (LUTS) and benign prostatic 
hyperplasia (BPH) are highly prevalent in older men. The 
prevalence and severity of LUTS increase with age [1]. In 
the EPIC study, a cross-sectional survey of 19,615 adults in 5 
countries, 62.5% of men reported having one or more LUTS 
[2]. The LUTS of BPH that relate to voiding tend to be most 
prevalent, and the symptoms related to storage are embar-
rassing and disruptive to daily life and tend to be more both-
ersome [3].
 The storage subcategory of LUTS is synonymous with 
overactive bladder (OAB) syndrome, which is defined by the 
International Continence Society as “urgency, with or with-
out urge incontinence, usually with frequency and nocturia” 
[4]. International differences in OAB prevalence have been 
observed. A multinational study in six European countries 
demonstrated significant variation in prevalence, with Spain 
reporting the highest (22%) prevalence and France reporting 
the lowest (12%) prevalence [5]. However, in Asian samples, 
the prevalence of OAB has been reported to be even higher. 
An OAB prevalence of about 30% was observed in the Asian 
male population (range, 14%–84%). Frequency and urgency 
were the most commonly reported symptoms, whereas 13% 
of individuals examined reported urge incontinence [6].
 Traditionally, alpha-blockers are widely prescribed to man-
age the LUTS of BPH, although storage symptoms may persist 
in many men despite treatment [7]. Therefore, because thera-
pies that target the prostate often fail to alleviate storage symp-
toms, they may not be the appropriate therapy for OAB. Addi-




alpha-1 receptor subtype present in prostatic tissue. Silodosin 
and tamsulosin are the alpha-1A-selective alpha receptor an-
tagonists and naftopidil is the alpha-1D-predominant recep-
tor antagonist. 
 Direct head-to-head comparisons between alpha receptor 
antagonists are limited. In a randomized double-blind place-
bo-controlled study, terazosin significantly increased Qmax 
(P< 0.001) and did not alter postvoided residual volume 
(PVR) at 24 weeks. In a pooled analysis of three double-blind 
placebo-controlled trials, there was also significant improve-
ment in total IPSS [20]. Doxazosin produced a significantly 
greater improvement than placebo in Qmax (P= 0.0017), 
symptom severity (P< 0.0001), and bother caused by symp-
toms (P< 0.0001) [21]. Another alpha-1 receptor antagonist, 
alfuzosin, was reported to significantly improve total IPSS 
(P< 0.005), IPSS storage subscore (P< 0.001), IPSS voiding 
subscore (P< 0.001), and Qmax (P< 0.001) compared with 
placebo [22]. In a meta-analysis of the outcome of 14 different 
tamsulosin studies, compared with placebo, tamsulosin was 
superior to placebo with an IPSS improvement of 12% (tam-
sulosin, 0.4 mg) and 16% (tamsulosin, 0.8 mg) [23]. A more 
recent drug, silodosin, showed efficacy equal to tamsulosin 
on study endpoints, but only silodosin significantly reduced 
nocturia versus placebo (change from baseline was –0.9, –0.8, 
and –0.7 for silodosin, tamsulosin, and placebo, respectively; 
P< 0.013 for silodosin vs. placebo) [24]. Naftopidil, most re-
cently approved in Korea, has distinct characteristics because 
it has three times greater affinity for the alpha-1D adrenergic 
receptor subtype than for the alpha-1A subtype [25]. Naftopi-
dil significantly improved the overall IPSS (from 19.2 ± 7.9 to 
11.7 ± 5.8, P< 0.001), QoL score (5.0 ± 0.8 to 3.6 ± 1.3, P< 0.001), 
and storage symptom score (8.6 ± 2.9 to 5.8 ±  3.3, P< 0.001) 
from baseline [26]. 
 Several studies have reported that alpha adrenergic recep-
tor antagonists can improve the storage symptoms in male 
BPH patients [27-29]. Tamsulosin [27,28] and silodosin [29] 
showed significant improvement in IPSS storage scores. Naf-
topidil also demonstrated a significant response to improve 
storage symptoms including daytime frequency and nocturia 
[30,31]. However, until now, the data were insufficient to sup-
port a recommendation for alpha-1 monotherapy for male 
LUTS combined with OAB. 
5-ALPHA REDUCTASE INHIBITORS
The enzyme 5-alpha reductase converts testosterone to dihy-
drotestosterone [32]. There are two isoforms of 5-alpha reduc-
tase: type 1 and type 2. Two 5-ARIs are available for clinical 
tionally, in clinical practice, it is difficult to treat patients who 
have BPH and OAB symptoms with an anticholinergic agent 
because of the possibility of acute urinary retention (AUR) [8]. 
The aim of this article was to provide a contemporary review 
of the current role of anticholinergic therapy in the treatment 
of male LUTS combined with OAB. 
TREATMENT OPTIONS FOR MEN WITH 
LUTS AND OAB
LUTS in men are often treated first with agents that target 
the prostate or bladder outlet obstruction (BOO; dynamic 
obstruction), such as 5-alpha reductase inhibitors (5-ARIs) 
and alpha receptor antagonists [9]. Men with LUTS/OAB are 
usually treated with BPH drugs rather than those specific for 
OAB, despite the high prevalence of coexistent storage symp-
toms in men with LUTS [10]. Many physicians are still reluc-
tant to prescribe anticholinergics owing to concern about 
urinary retention, especially in men with BOO. However, sev-
eral studies have reported that prescribing anticholinergics 
to men with LUTS or even BOO does not seem to elevate the 
risk of AUR [11,12]. 
ALPHA RECEPTOR ANTAGONISTS
Alpha receptor antagonists are considered the first-line treat-
ment for LUTS [13]. Alpha receptor antagonists decrease 
smooth muscle tone in the prostate and bladder neck [14]. 
Because LUTS in men have traditionally been attributed to 
BPH and obstructed urinary flow, pharmacological therapies 
have been aimed at improving urinary flow rates rapidly and 
optimizing voiding efficiency [15]. According to the European 
Association of Urology guidelines, alpha-blockers should be 
offered to men with moderate to severe LUTS and are consid-
ered the first-line drug treatment for these patients [16]. The 
American Urologic Association Clinical Practice Guidelines 
Committee determined that alfuzosin, doxazosin, tamsulo-
sin, and terazosin are all appropriate treatment options for 
patients with LUTS secondary to BPH [13]. Placebo-con-
trolled studies have shown that α1-blockers typically reduce 
the International Prostate Symptom Score (IPSS) by approxi-
mately 35% to 40%. Furthermore, the maximum urinary flow 
rate (Qmax) increases by approximately 20% to 25% [17-19]. 
 The main alpha receptor antagonists used for treating 
LUTS in men with BPH are alfuzosin, doxazosin, terazosin, 
tamsulosin, silodosin, and the more recent drug, naftopidil. 
In the male prostate and urethra, the alpha-1A receptor sub-
type is most prevalent. These drugs are all selective for the 




than in those given placebo (0 mL, P< 0.004). In another 
study, fesoterodine 4 or 8 mg resulted in significantly greater 
improvements in micturition frequency, urgency episodes, 
and urgency urinary incontinence episodes compared with 
placebo in men with OAB [45]. 
 Although studies in elderly men with LUTS and OAB 
symptoms were exclusively carried out with tolterodine or fe-
soterodine, it is likely that similar efficacy and adverse events 
will also be shown with other antimuscarinic agents. Long-
term studies on the efficacy of muscarinic receptor antago-
nists in men with LUTS are still lacking; therefore, these drugs 
should be prescribed with caution, and regular re-evaluation 
of IPSS and PVR urine is advised [13,16]. 
COMBINATION TREATMENT: ALPHA RE-
CEPTOR ANTAGONISTS + ANTIMUSCA-
RINIC AGENTS 
Even after treatment with alpha receptor antagonists and 
5-ARIs, many patients with BPH/LUTS suffer from persistent 
symptoms of OAB. In recent years, a number of studies have 
reported on the combination treatment of alpha receptor 
antagonists and antimuscarinic agents [12,41-47]. In a 2006 
study by Kaplan et al. [48] named the TIMES study, tolt-
erodine extend release (ER) and tamsulosin combination 
treatment resulted in significant improvement in urgency 
episodes, number of micturitions, nocturia, and IPSS. The 
medication was well tolerated with no significant differences 
in voiding pattern, PVR, or episodes of AUR. A subanalysis 
of the TIMES study combination treatment with tamsulosin 
and tolterodine ER showed significant improvements in IPSS 
storage symptom scores compared with placebo. A recent 
phase II study [49], a dose-finding study of solifenacin and 
tamsulosin in males with LUTS associated with BPH (the 
SATURN study), was designed to investigate the combination 
of tamsulosin and solifenacin versus tamsulosin alone and 
placebo in the treatment of men with LUTS. Combination 
therapy was associated with significant improvements in mic-
turition frequency and voided volume versus the tamsulosin 
oral controlled absorption system alone. In addition, signifi-
cant improvement was found in the IPSS storage subscore in 
all the combination groups compared with tamsulosin alone. 
In another recent study [50], the combination of solifenacin 
6 mg and the tamsulosin oral controlled absorption system 
significantly improved storage and voiding symptoms, as 
well as QoL parameters, over placebo. In the ADAM study 
[51], combination therapy with alpha receptor antagonists 
and tolterodine sustained release resulted in significantly 
use. Dutasteride has a dual mechanism and inhibits type 1 
and type 2 5-alpha reductase, whereas finasteride inhibits 
only 5-alpha reductase type 2. These inhibitors induce apop-
tosis of prostate epithelial cells, which results in a decrease 
of prostate size by about 18% to 20% and of prostate-specific 
antigen levels by about 50% after 6 to 12 months of treatment 
[33]. Finasteride significantly improves symptom scores (P< 
0.001 and P<0.015) and Qmax (P<0.001) compared with 
placebo after 12 months of use [34]. A meta-analysis of these 
early studies concluded that these improvements were less 
in patients with a smaller prostate [35]. Dutasteride also 
showed symptom scores from 6 months onward (P<0.001) 
with a mean improvement of 4.5 points at 24 months [36]. The 
Qmax improved significantly from 1 month (P<0.01) with an 
increase of 2.2 mL/s reported at 24 months (P<0.001). In a 
head-to-head trial of the two drugs, Qmax, prostate volume, 
and LUTS variation were similar for both drugs [37]. However, 
it remains to be elucidated whether 5-ARI monotherapy can 
improve the storage component of male LUTS, particularly 
male OAB symptoms. 
ANTIMUSCARINIC AGENTS 
Antimuscarinic agents are considered the first-line treatment 
for patients with OAB. These agents act by blocking acetylcho-
line binding at muscarinic receptors on the detrusor muscle, 
thereby reducing the ability of the detrusor to contract during 
the voiding phase [38]. Antimuscarinic agents improve the 
storage symptom of urgency and increase bladder capacity, 
whereas their effects decrease during the voiding phase when 
a massive release of acetylcholine from cholinergic nerves is 
present [39]. 
 In clinical practice, many physicians are reluctant to pre-
scribe antimuscarinic agents in male patients with LUTS com
bined with OAB owing to the concern of urinary retention. 
However, several studies have reported that prescribing anti-
muscarinic agents to men with LUTS or even BOO does not 
seem to elevate the risk of AUR [11,40]. The results of several 
studies support the efficacy and safety of antimuscarinics 
in treating men with LUTS and OAB [41-44]. For example, 
Abrams et al. [11] reported the efficacy of tolterodine imme-
diate-release in men with both BOO and OAB. Tolterodine 
significantly reduced the BOO index (–0.9 vs. 0, P< 0.02) and 
increased maximal cystometric capacity (+67 mL; 95% con-
fidence interval, 35–103; P< 0.003) compared with placebo. 
No significant differences in the incidence of adverse events 
were seen, whereas the change in PVR was significantly 
higher among patients treated with tolterodine (+25 mL) 




greater improvements versus placebo plus alpha-blocker in 
24-hour micturitions, daytime micturitions, 24-hour urgency 
episodes, daytime urgency episodes, nocturnal urgency epi-
sodes, frequency–urgency sum, IPSS storage subscale, OAB-q 
symptom bother scale, and OAB-q coping domain at week 12. 
 Lee et al. [43,44] recently reported that initial combined 
treatment with alpha receptor antagonists plus an anti-
muscarinic agent showed improvement in not only storage 
symptoms but also QoL scores without increasing the risk of 
AUR. In recognition of the growing body of evidence for the 
use of antimuscarinics for storage symptoms in men, the 6th 
International Consultation on New Developments in Pros-
tate Cancer and Prostate Disease recommended the use of 
combination therapy with alpha-blockers for men with BOO 
mixed with OAB [52]. However, there seems to be a discrep-
ancy between the awareness of urologists and their actual 
practice patterns in the treatment of men with BOO mixed 
with OAB owing to fear of AUR [10]. 
5-ARIs AND ANTIMUSCARINIC AGENTS
Recently, Chung et al. [53] reported that combination therapy 
with 5-ARIs and antimuscarinic agents is safe and effective in 
men with LUS/BPH. Tolterodine ER with 0.5 mg dutasteride 
was given to men with persistent OAB symptoms and LUTS 
that were unsuccessfully treated with dutasteride alone. All 
patients were given 4 mg tolterodine ER daily for 12 weeks 
and maintained on dutasteride. The total IPSS decreased 
with dutasteride treatment from 19.3 to 14.3 and further 
decreased with the addition of tolterodine to 7.1 (P< 0.001). 
Storage symptoms decreased from 9.8 to 4.5 after tolterodine 
(P< 0.001). In this study, the combination of tolterodine ER 
and dutasteride was effective, safe, and well-tolerated in men 
with large prostates ( ≥ 30 mL) with persistent OAB symptoms 
and LUTS/BPH. 
BETA-3 ADRENORECEPTOR AGONISTS 
The beta-3 adrenoreceptor subtype is the predominant form 
of beta adrenoceptor in the bladder [54]. Its stimulation is as-
sociated with increased bladder capacity without a change in 
micturition pressure, PVR, or voiding contraction [55,56]. Nit-
ti et al. [57] reported that 40 mg mirabegron showed a statisti-
cally significant decrease in urgency episodes and micturition 
frequency without adversely affecting voiding urodynamics. 
Although these findings showing the urodynamic safety of 
mirabegron in men with LUTS and BOO are very promising, 
more randomized controlled trials are needed for positioning 
a new therapy for LUTS and OAB. 
CONCLUSION 
The treatment of BPH/LUTS combined with OAB is slowly but 
constantly evolving. In past years, most physicians appeared 
to give more weight in elderly men to voiding symptoms than 
to storage symptoms, and they are more concerned with 
initial treatment with anticholinergics for males with stor-
age symptoms. However, antimuscarinic therapy alone or in 
combination with alpha receptor antagonists improves OAB 
symptoms in men with or without BOO. The concern regard-
ing antimuscarinic use leading to an increased incidence of 
urinary retention appears to be unfounded. Therefore, the 
standard pharmacologic treatment of patients with LUTS 
combined with OAB should be an alpha receptor antagonist 
and an antimuscarinic agent. Beta-3 adrenoreceptor agonists 
may also be potentially useful for the treatment of male LUTS 
combined with OAB. 
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